We've all had occasion, each one of us here at this table, to interact with those countries. We've actually prepared a list, in addition to the website that we established, and the online users guide and the CD-ROM that we've distributed, of all the outreach activities we've engaged in. It's quite a lengthy one.
At least from my part, from what I've heard.... It's threefold, basically. I've given presentations on the regime to the African group at the TRIPS Council in Geneva and to various African delegations. Initially what I heard was that they're more interested in technology transfer--understandably so. They want to be able to take care of their public health issues themselves in time. That's one thing.
The other is that they lack the administrative infrastructure to actually avail themselves of this. As I mentioned at the outset, there a number of strict terms and conditions under the waiver that importing countries have to abide by. That includes figuring out whether the drug is patented in that country and indicating, if it is patented, whether they've issued or can issue a compulsory licence. If they're not a least developed country, they have to indicate that they have insufficient or no manufacturing capacity to produce the drug.
It sounds fairly simple to people in developed countries, but to them it does seem to pose a barrier to use.
And then the last thing is financial resources, and that's obvious.